EMA Authorised: Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron) (Dinutuximab beta) — Recordati Netherlands B.V.

View source ↗

Summary

The EMA authorised Qarziba (dinutuximab beta) for neuroblastoma, with orphan medicine status, under Recordati Netherlands B.V. as the marketing authorisation ho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Qarziba (Dinutuximab beta)

Snippet

Status: Authorised. Therapeutic area: Neuroblastoma. MAH: Recordati Netherlands B.V.. Decision date: 26/11/2025. Orphan medicine